methyl 5-bromo-2-(4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate | 883876-23-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: methyl 5-bromo-2-(4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate
• 英文别名: methyl 5-bromo-2-[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-1-(2-trimethylsilylethoxymethyl)imidazole-4-carboxylate
• CAS: 883876-23-1
• 化学式: C₂₁H₂₉BrF₃N₅O₃Si
• 分子量: 564.478
• InChiKey: SHQQKHKNAXAMMO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.48
• 重原子数：
  34
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  72.7
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  methyl 5-bromo-2-(4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate 在 三氟乙酸 作用下， 反应 1.0h， 以75%的产率得到methyl 5-bromo-2-[4-[3-(trifluoromethyl)pyridin-2-yl]piperazin-1-yl]-1H-imidazole-4-carboxylate
  参考文献：
  名称：

  Structure–activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists

  摘要：

  A novel series of 4,5-biarylimidazoles as TRPV1 antagonists were designed based on the previously reported 4,6-disubstituted benzimidazole series. The analogs were evaluated for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. These studies led to the identification of a highly potent and orally bioavailable TRPV1 antagonist, imidazole 33. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.08.044
• 作为产物：
  描述：

  methyl 2,5-dibromo-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate 、 1-[3-(三氟甲基)吡啶-2-基]哌嗪 在 silica gel 、 EtOAc Hexanes 作用下， 反应 0.25h， 生成 methyl 5-bromo-2-(4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole-4-carboxylate
  参考文献：
  名称：

  Vanilloid receptor ligands and their use in treatments

  摘要：

  治疗苯并咪唑类药物及其组合物，用于治疗急性、炎症性和神经病性疼痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合症、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠病、炎症性眼疾、炎症性或不稳定膀胱疾病、银屑病、具有炎症成分的皮肤疾病、慢性炎症状况、炎症性疼痛和相关的过敏症和痛觉过敏、神经病性疼痛和相关的过敏症和痛觉过敏、糖尿病神经病疼痛、烧伤后神经病疼痛、交感神经维持性疼痛、感觉神经缺失综合症、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、胃肠或血管区域内脏动力障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死剂引起的胃损伤、毛发生长、血管运动或过敏性鼻炎、支气管疾病或膀胱疾病。

  公开号：

  US20060084640A1

文献信息

• Vanilloid receptor ligands and their use in treatments
  申请人：Gore Keshav Vijay

  公开号：US20060084640A1

  公开（公告）日：2006-04-20

  Therapeutic benzimidazoles and compositions containing them, for the treatment of acute, inflammatory and neuropathic pain, dental pain, general headache, migraine, cluster headache, mixed-vascular and non-vascular syndromes, tension headache, general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, inflammatory pain and associated hyperalgesia and allodynia, neuropathic pain and associated hyperalgesia and allodynia, diabetic neuropathy pain, causalgia, sympathetically maintained pain, deafferentation syndromes, asthma, epithelial tissue damage or dysfunction, herpes simplex, disturbances of visceral motility at respiratory, genitourinary, gastrointestinal or vascular regions, wounds, burns, allergic skin reactions, pruritus, vitiligo, general gastrointestinal disorders, gastric ulceration, duodenal ulcers, diarrhea, gastric lesions induced by necrotising agents, hair growth, vasomotor or allergic rhinitis, bronchial disorders or bladder disorders.

  治疗性苯并咪唑及含有它们的组合物，用于治疗急性、炎症性和神经痛、牙痛、普通头痛、偏头痛、集群头痛、混合血管和非血管综合征、紧张性头痛、一般炎症、关节炎、风湿性疾病、骨关节炎、炎症性肠道疾病、炎症性眼部疾病、炎症性或不稳定的膀胱疾病、牛皮癣、带有炎症成分的皮肤疾病、慢性炎症症状、炎症性疼痛及相关的过敏性疼痛和触痛、神经痛及相关的过敏性疼痛和触痛、糖尿病性神经病痛、烧灼性疼痛、交感神经维持性疼痛、去神经症候群、哮喘、上皮组织损伤或功能障碍、单纯疱疹、呼吸、泌尿、消化或血管区域内脏运动障碍、伤口、烧伤、过敏性皮肤反应、瘙痒、白癜风、一般胃肠道疾病、胃溃疡、十二指肠溃疡、腹泻、由坏死性剂引起的胃病变、毛发生长、血管运动性或过敏性鼻炎、支气管疾病或膀胱疾病。
• Structure–activity relationship (SAR) investigations of substituted imidazole analogs as TRPV1 antagonists
  作者：Vijay K. Gore、Vu V. Ma、Rami Tamir、Narender R. Gavva、James J.S. Treanor、Mark H. Norman

  DOI：10.1016/j.bmcl.2007.08.044

  日期：2007.11

  A novel series of 4,5-biarylimidazoles as TRPV1 antagonists were designed based on the previously reported 4,6-disubstituted benzimidazole series. The analogs were evaluated for their ability to block capsaicin- or acid-induced calcium influx in TRPV1-expressing CHO cells. These studies led to the identification of a highly potent and orally bioavailable TRPV1 antagonist, imidazole 33. (c) 2007 Elsevier Ltd. All rights reserved.